4-1-1 本所及经办律师依据上述规定以及本法律意见书出具日以前已经发生或者 存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则，对发行人 本次发行相关事项进行了充分的核查验证，保证本法律意见书所认定的事实真实、 准确、完整，对本次发行上市所发表的结论性意见合法、准确，不存在虚假记载、 误导性陈述或者重大遗漏，并承担相应法律责任。 4-1-2 北京市金杜律师事务所 关于北京神州细胞生物技术集团股份公司 2025 年度向特定对象发行 A 股股票的 法律意见书 致：北京神州细胞生物技术集团股份公司 北京市金杜律师事务所（以下简称"本所"）接受北京神州细胞生物技术集 团股份公司（以下简称"发行人"）委托，担任发行人 2025 年度向特定对象发 行 A 股股票（以下简称"本次发行"）的专项法律顾问。 本所根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人 民共和国公司法》（以下简称"《公司法》"）、《上市公司证券发行注册管理办 法》（以下简称"《证券发行注册管理办法》"）、《律师事务所从事证券法律业 务管理办法》（以下简称"《证券法律业务管理办法》"）、《律师事务所证券法 律业务执业规则（试行 ...

2024 年度 审计报告 | 索引 | 页码 | | --- | --- | | 审计报告 | 1-5 | | 公司财务报表 | | | 合并资产负债表 | 1-2 | | 母公司资产负债表 | 3-4 | | 合并利润表 | 5 | | 母公司利润表 | 6 | | 合并现金流量表 | 7 | | 母公司现金流量表 | 8 | | 合并股东权益变动表 | 9-10 | | 母公司股东权益变动表 | 11-12 | | 财务报表附注 | 13-98 | 6-1-1 北京神州细胞生物技术集团股份公司 ica 北京市东城区朝阳门北大街 8 号富华大厦 A 座 9 层 9/F Block A. Fu Hua Mansio No 8 Chaovangmen Beida Donacheng District. Beijin 审计报告 XYZH/2025BJAA1B0445 北京神州细胞生物技术集团股份公司 北京神州细胞生物技术集团股份公司全体股东: 一、审计意见 我们审计了北京神州细胞生物技术集团股份公司(以下简称神州细胞公司)财务报 表,包括 2024年 12月 31日的合并及母公司资产负债表,2024年度的合并及母 ...

Core Viewpoint - The company Shenzhou Cell is embroiled in a series of medical insurance fraud cases involving its product, Anjain, which is a recombinant human coagulation factor VIII for hemophilia A patients. Investigations are ongoing, and several patients and sales representatives are implicated in fraudulent activities related to insurance claims [1][4][5]. Group 1: Company Overview - Shenzhou Cell's Anjain is the first domestically approved recombinant human coagulation factor VIII in China, launched in 2021, primarily for controlling and preventing bleeding in hemophilia A patients aged 12 and older [2]. - The company claims to adhere to legal and compliance standards, emphasizing that the actions of individual sales representatives do not reflect the overall operational strategy of the company [4][20]. - Following the launch of Anjain, the price of recombinant factor VIII has decreased by nearly 50% due to national drug procurement policies [4]. Group 2: Fraud Allegations - The allegations involve Shenzhou Cell's sales team collaborating with patients to fraudulently obtain insurance reimbursements by misrepresenting medical conditions, leading to significant financial gains from the insurance fund [5][11]. - A specific case highlighted that a patient fraudulently obtained over 1.19 million yuan in reimbursements, with the company allegedly providing a 4% rebate on the medication costs to patients [5][19]. - The legal framework stipulates that adult hemophilia patients are only eligible for insurance reimbursement when they exhibit bleeding symptoms, making the fraudulent claims particularly egregious [8][11]. Group 3: Market Impact - Anjain has rapidly gained market share, becoming the leading product in its category within three years of its launch, attributed to its lower price compared to foreign competitors [16]. - The company has established a charitable assistance program that allows patients to receive treatment at no cost, effectively covering the out-of-pocket expenses through partnerships with charitable organizations [17][20]. - The sales strategy has reportedly enabled patients to receive not only free treatment but also cash rebates, creating a controversial but effective market penetration model [18][19]. Group 4: Legal and Compliance Issues - Legal experts indicate that the sales representatives may face significant legal consequences, as their actions reflect a clear understanding of the fraudulent nature of their activities, despite claims of merely following company directives [15][21]. - The company has publicly stated its commitment to compliance and has denied any involvement in fraudulent activities, asserting that any misconduct by individual employees does not represent the company's practices [4][20].

Group 1 - The restructuring protein concept declined by 0.85%, ranking among the top declines in the concept sector, with leading decliners including Beida Pharmaceutical, Saiseng Pharmaceutical, and Rejing Bio [1][2] - Among the 39 stocks in the restructuring protein sector, 18 stocks saw price increases, with Zhongyuan Qihua, Huaxi Bio, and *ST Wanfang leading the gains at 3.27%, 2.53%, and 2.23% respectively [1][2] - The restructuring protein sector experienced a net outflow of 789 million yuan from main funds today, with Shenzhou Cell seeing the largest outflow of 75.26 million yuan [2][3] Group 2 - The top gainers in the concept sector included Tonghuashun Fruit Index at 3.70%, AI Mobile at 2.77%, and National Big Fund Holdings at 2.76%, while the monkeypox concept declined by 0.86% [2] - The main funds saw net inflows in stocks such as Huaxi Bio, Guoyao Modern, and Haoyuan Pharmaceutical, with inflows of 47.54 million yuan, 21.85 million yuan, and 20.45 million yuan respectively [2][4] - The restructuring protein concept's outflow list included stocks like Shenzhou Cell, Ruizhi Pharmaceutical, and Kexing Pharmaceutical, with respective outflows of 75.26 million yuan, 70.92 million yuan, and 65.90 million yuan [2][3]

Core Insights - The stock price of ShenZhou Cell is reported at 71.40 yuan, down by 1.60 yuan or 2.19% from the previous trading day [1] - The company operates in the biopharmaceutical industry, focusing on the development of innovative biological drugs, including recombinant protein drugs and monoclonal antibody drugs for treating cancer and autoimmune diseases [1] - Recent data indicates a significant increase in ShenZhou Cell's financing balance, with a growth rate exceeding 95%, reflecting heightened market interest in the company [1] Trading Activity - On August 19, the net inflow of main funds was 139 million yuan, accounting for 0.44% of the circulating market value [1] - Over the past five trading days, the cumulative net inflow of funds reached 424 million yuan, representing 1.33% of the circulating market value [1] - The stock opened at 72.99 yuan, peaked at 78.84 yuan, and dipped to a low of 71.00 yuan, with a trading volume of 145,500 hands and a transaction amount of 1.087 billion yuan [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Shenzhou Cell, which has a high PE ratio compared to its industry peers [1][2] - As of August 19, Shenzhou Cell's stock closed at 71.4 yuan, down 2.19%, with a rolling PE ratio of 313.20 and a total market capitalization of 31.797 billion yuan [1] - The average PE ratio for the biopharmaceutical industry is 73.41, with a median of 45.28, placing Shenzhou Cell at the 72nd position among its peers [1][2] Group 2 - As of the first quarter of 2025, 17 institutions hold shares in Shenzhou Cell, with a total of 2.7733 million shares valued at 166 million yuan [1] - The company specializes in the research and commercialization of biopharmaceutical products for various diseases, including cancer and autoimmune diseases, with key products such as SCT800 and SCT400 [1] - In the latest financial report for the first quarter of 2025, Shenzhou Cell reported a revenue of 520 million yuan, a year-on-year decrease of 15.15%, and a net profit of 63.768 million yuan, down 14.06%, with a gross margin of 94.88% [1]

Core Viewpoint - The financial performance of Youyan Silicon in the first half of 2025 shows a decline in revenue and profit, reflecting ongoing challenges in the semiconductor materials industry due to increased competition and market demand fluctuations [1][5]. Financial Performance - In the first half of 2025, Youyan Silicon reported revenue of 491 million RMB, a decrease of 3.2% year-on-year [2]. - The net profit attributable to shareholders was 106 million RMB, down 18.7% compared to the same period last year [1][2]. - The net profit after deducting non-recurring gains and losses was 73.6 million RMB, a decline of 19.5% year-on-year [2]. - For the second quarter of 2025, revenue was 260 million RMB, a 4.5% decrease year-on-year, with net profit falling to 56.9 million RMB, down 23.1% [1][2]. Industry Context - The semiconductor materials industry is experiencing a slowdown, with increased competition leading to price pressures from downstream semiconductor device manufacturers [5]. - The market is seeing a structural divide, with strong demand for storage and logic chips driven by AI technology, while the power semiconductor sector faces challenges due to weak demand in automotive electronics and industrial markets [5][6]. - Youyan Silicon's main product, 8-inch silicon wafers, saw a significant sales increase of 60% year-on-year, yet profits continue to decline due to market conditions [4][5]. Strategic Moves - In response to industry challenges, Youyan Silicon acquired a 70% stake in Japanese company DG Technologies to enhance its semiconductor core component processing technology [8]. - The company announced an investment of 48.33 million RMB to develop an 8-inch zone melting silicon single crystal project, aiming to enter the high-voltage power device market [8].

Market Overview - The biopharmaceutical sector increased by 0.27% on August 19, with Olin Bio leading the gains [1] - The Shanghai Composite Index closed at 3727.29, down 0.02%, while the Shenzhen Component Index closed at 11821.63, down 0.12% [1] Top Performers - Olin Bio (688319) closed at 31.21, up 12.71% with a trading volume of 275,600 shares and a transaction value of 831 million [1] - Nossland (430047) closed at 28.44, up 11.53% with a trading volume of 211,700 shares and a transaction value of 622 million [1] - Ganli Pharmaceutical (603087) closed at 68.03, up 6.95% with a trading volume of 406,100 shares and a transaction value of 2.793 billion [1] Underperformers - Junshi Biosciences (688180) closed at 45.32, down 3.70% with a trading volume of 210,400 shares and a transaction value of 977 million [2] - ZhiXiangQuanTai (688443) closed at 33.05, down 3.42% with a trading volume of 77,200 shares and a transaction value of 260 million [2] - SanShengGuoJian (688336) closed at 54.10, down 2.50% with a trading volume of 85,900 shares and a transaction value of 477 million [2] Capital Flow - The biopharmaceutical sector saw a net inflow of 250 million from institutional investors, while retail investors experienced a net outflow of 379 million [2][3] - Major stocks like Shenzhou Cell (688520) had a net inflow of 1.39 billion from institutional investors, but a net outflow of 1.08 billion from retail investors [3]

Group 1 - The total margin balance of the Sci-Tech Innovation Board reached 190.27 billion yuan on August 15, an increase of 0.99 billion yuan from the previous trading day [1] - The financing balance amounted to 189.643 billion yuan, increasing by 1.018 billion yuan, while the securities lending balance was 0.627 billion yuan, decreasing by 0.03 billion yuan [1] - A total of 255 stocks on the Sci-Tech Innovation Board experienced net financing inflows, with 16 stocks having net inflows exceeding 50 million yuan [1] Group 2 - Cambricon Technologies led the net financing inflow with an amount of 183 million yuan, followed by Huahong Semiconductor, Sino Medical, East China Semiconductor, Tengjing Technology, SMIC, and Shenzhou Cell with net inflows of 127 million yuan, 121 million yuan, 115 million yuan, 106 million yuan, 102 million yuan, and 99 million yuan respectively [1]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688276 | 百克生物 | 25.40 | 8.09% | 11.19万 | 2.75亿 | | 688520 | 神州细胞 | 73.20 | 6.94% | 15.40万 | 11.00亿 | | 688331 | 荣昌生物 | 76.99 | 4.35% | - 14.02万 | 10.53亿 | | 300239 | 东宝生物 | 5.94 | 3.85% | 19.94万 | 1.17亿 | | 688163 | 赛伦生物 | 26.15 | 3.81% | 2.75万 | 7126.14万 | | 300841 | 康华生物 | 92.06 | 3.67% | 6.31万 | 5.74亿 | | 301166 | 优宁维 | 33.75 | 2.99% | 1.91万 | 6363.30万 | | 688177 | 百圆泰 | 33.29 | 2.91% | 4.75万 | 1.56亿 | | 600739 | 辽宁成大 | + 1 ...